DOI QR코드

DOI QR Code

Immunopreventive Effects against Murine H22 Hepatocellular Carcinoma in vivo by a DNA Vaccine Targeting a Gastrin-Releasing Peptide

  • Meko'o, Jean Louis Didier ;
  • Xing, Yun ;
  • Zhang, Huiyong ;
  • Lu, Yong ;
  • Wu, Jie ;
  • Cao, Rongyue
  • Published : 2014.11.06

Abstract

There is a continuing need for innovative alternative therapies for liver cancer. DNA vaccines for hormone/growth factor immune deprivation represent a feasible and attractive approach for cancer treatment. We reported a preventive effect of a DNA vaccine based on six copies of the B cell epitope GRP18-27 with optimized adjuvants against H22 hepatocarcinoma. Vaccination with pCR3.1-VS-HSP65-TP-GRP6-M2 (vaccine) elicited much higher level of anti-GRP antibodies and proved efficacious in preventing growth of transplanted hepatocarcinoma cells. The tumor size and weight were significantly lower (p<0.05) in the vaccine subgroup than in the control pCR3.1-VS-TP-HSP65-TP-GRP6, pCR3.1-VS-TP-HSP65-TP-M2 or saline subgroups. In addition, significant reduction of tumor-induced angiogenesis associated with intradermal tumors of H22 cells was observed. These potent effects may open ways towards the development of new immunotherapeutic approaches in the treatment of liver cancer.

Keywords

Liver cancer;naked DNA;anti-GRP;anti-angiogenesis;anti-tumor

References

  1. Beer M, Montari M, Gerhard J, et al (2012). Profiling gastrinreleasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate, 72, 318-22 https://doi.org/10.1002/pros.21434
  2. Bele T (2012). Treating cancer with vaccine. Web Med Central Immunopathol, 3, 3267.
  3. Boehm T, Folkman J, Browder T, et al (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-7. https://doi.org/10.1038/37126
  4. Butterfield LH (2007). Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly, 137, 83-90.
  5. Donnelly JJ, Ulmer JB, Shiver JW, et al (1997). DNA vaccines. Ann Rev Immunol, 15, 617-48. https://doi.org/10.1146/annurev.immunol.15.1.617
  6. Egloff AM, Davis AG, Shuai YL, et al (2012). Gastrin-releasing expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respiratory Research, 13, 9. https://doi.org/10.1186/1465-9921-13-9
  7. Fang F, Lu Y, Ouyang K, et al (2009). Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. Clin Vaccine Immunol, 16, 1033-39. https://doi.org/10.1128/CVI.00046-09
  8. Folkman F (1996). Fighting cancer by attacking its blood supply. Sci Am, 275, 150-4. https://doi.org/10.1038/scientificamerican0996-150
  9. Gruber M, Simon MC (2006). Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol, 13, 169-74. https://doi.org/10.1097/01.moh.0000219663.88409.35
  10. Folkman F (1997). Antiangiogenic Therapy. In Principles and Practice of Oncology. 9th Ed DeVita V T, Hellman S, Rosenberg SA, Lippincott Williams & Wilkins (LWW) Philadelphia: Lippincott- Raven) pp 3075-85 Number 978-2.
  11. Gordan JD, Simon MC (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev, 17, 71-77. https://doi.org/10.1016/j.gde.2006.12.006
  12. Greten TF, Papendorf F, Bleck JS, et al (2006). Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer, 92, 1862-8.
  13. Hohla F, Schally AV (2010). Targeting gastrin releasing receptors New options for the therapy and diagnosis of cancer. Cell Cycle, 9, 1738-41. https://doi.org/10.4161/cc.9.9.11347
  14. Huang J, Soffer SZ, Kim ES, et al (2004). Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res, 2, 36-42.
  15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69. https://doi.org/10.3322/caac.20107
  16. Kang J, Ishola TA, Baregamian N, et al (2007). Chung, Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett, 253, 273-81. https://doi.org/10.1016/j.canlet.2007.02.007
  17. Kreisle RA, Ershler WB (1988). Investigation of tumor angiogenesis in an id mouse model: role of host-tumor interactions. J Natl Can Inst, 80, 849-54. https://doi.org/10.1093/jnci/80.11.849
  18. Lee S, Qiao JB, Pritha P, et al (2013). Integrin $\beta{1}$ critical fro gastrin-releasing peptide receptor-mediated neuroblastoma cell migration and invasion. Surgery, 154, 369-75. https://doi.org/10.1016/j.surg.2013.04.067
  19. Lee SY, Kang TH, Knoff J, et al (2013). Enhanced anticancer immunotherapy with a DNA vaccine by depleting platelets. J Immunother Can, 1, 222. https://doi.org/10.1186/2051-1426-1-S1-P222
  20. Martins FF, Contu PC, Meurer L, et al (2013). Expression of gastrin-releasing peptide receptor in epidermoid carcinoma of anal canal. Appl Immunohistochem Mol Morphol.
  21. Levine L, Lucci JA, Pazdrak B, et al (2003). Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res, 63, 3495-502.
  22. Lu Y, Ouyang K, Fang J, et al (2009). Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine, 27, 5418-511.
  23. Luigi A and Ciliberto G (2011). Emerging cancer vaccines: The promise of genetic vectors. Cancers, 3, 3687- 713. https://doi.org/10.3390/cancers3033687
  24. Matejuk A, Leng Q, Chou ST, et al (2011). Vaccines targeting the neovasculature of tumors. Vasc Cell, 3, 7. https://doi.org/10.1186/2045-824X-3-7
  25. Ni CS, Zhao XL, Sun T, et al (2012). Role of gastrin-releasing peptide in breast cancer metastasis. Human Pathol, 12, 2342-47.
  26. Ozturk M and Oters S (2011). Molecular approach to treatment of hepatocellular carcinoma: New hope for therapeutic targets. J Exper Integr Med, 1, 83-4.
  27. Pirtha P, Qiao JB, Kim KW, et al (2013). Targeting gastrin-releasing peptide suppresses neuroblastoma progression via upregulation of PTEN signaling. PLoSONE, 8, 72570 https://doi.org/10.1371/journal.pone.0072570
  28. Ray K (2013). The promise of new approaches in the management of hepatocellular carcinoma adding to the toolbox? Nat Rev Gastroenterol Hepathol, 10.
  29. Rinaldi M, Lurescia S, Fioretti D, et al (2009). Strategies for successful vaccination against hepatocellular carcinoma. Int J Immunopathol Pharmacol, 22, 269-77.
  30. Rosen LS (2009). Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control, 9, 36-44.
  31. Wu G, Guo W, Ouyan K, et al (2008). A novel vaccine targeting gastrinreleasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer, 15, 149-59. https://doi.org/10.1677/ERC-07-0224
  32. Yankai Z, Rong Y, Yi L, Wentao L, et al (2006). Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of betahCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Biochem Biophys Res Commun, 345, 1365-71. https://doi.org/10.1016/j.bbrc.2006.05.022
  33. Zhu XA, Duda DG, Sahani DV, et al (2011). HCC and angiogenesis: Possible targets and future direction. Nat Rev Clin Oncol, 8, 292-301. https://doi.org/10.1038/nrclinonc.2011.30

Cited by

  1. Solanum Nigrum Polysaccharide (SNL) Extract Effects in Transplanted Tumor-bearing Mice - Erythrocyte Membrane Fluidity and Blocking of Functions vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10469